Nothing Special   »   [go: up one dir, main page]

Jiang et al., 2008 - Google Patents

Ang II–stimulated migration of vascular smooth muscle cells is dependent on LR11 in mice

Jiang et al., 2008

View HTML
Document ID
8935069001880113136
Author
Jiang M
Bujo H
Ohwaki K
Unoki H
Yamazaki H
Kanaki T
Shibasaki M
Azuma K
Harigaya K
Schneider W
Saito Y
et al.
Publication year
Publication venue
The Journal of clinical investigation

External Links

Snippet

Medial-to-intimal migration of SMCs is critical to atherosclerotic plaque formation and remodeling of injured arteries. Considerable amounts of the shed soluble form of the LDL receptor relative LR11 (sLR11) produced by intimal SMCs enhance SMC migration in vitro …
Continue reading at www.jci.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes

Similar Documents

Publication Publication Date Title
Jiang et al. Ang II–stimulated migration of vascular smooth muscle cells is dependent on LR11 in mice
Iismaa et al. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders
Osonoi et al. Defective autophagy in vascular smooth muscle cells enhances cell death and atherosclerosis
Egaña-Gorroño et al. Receptor for advanced glycation end products (RAGE) and mechanisms and therapeutic opportunities in diabetes and cardiovascular disease: insights from human subjects and animal models
Oldoni et al. ANGPTL8 has both endocrine and autocrine effects on substrate utilization
Tang et al. Endothelial HIF-2α contributes to severe pulmonary hypertension due to endothelial-to-mesenchymal transition
Kapur et al. Endoglin: a critical mediator of cardiovascular health
Wang et al. The hypoxia-inducible factor α pathway couples angiogenesis to osteogenesis during skeletal development
Al-Yafeai et al. Endothelial FN (Fibronectin) deposition by α5β1 integrins drives atherogenic inflammation
Lillis et al. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies
Yoshimoto et al. The discovery of LOX-1, its ligands and clinical significance
Weston et al. Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis
Fond et al. Apoptotic cells trigger a membrane-initiated pathway to increase ABCA1
Moulton et al. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis
Sheikh et al. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure
Bauman et al. The antifibrotic effects of plasminogen activation occur via prostaglandin E 2 synthesis in humans and mice
Gutierrez et al. Thrombospondin 1 in metabolic diseases
Shi et al. Syndecan-2 exerts antifibrotic effects by promoting caveolin-1–mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling
Hasumi et al. Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation
Miyake et al. Regression of abdominal aortic aneurysms by simultaneous inhibition of nuclear factor κB and ets in a rabbit model
Moura et al. Thrombospondin-1 activates medial smooth muscle cells and triggers neointima formation upon mouse carotid artery ligation
Besschetnova et al. Regulatory mechanisms of anthrax toxin receptor 1-dependent vascular and connective tissue homeostasis
Rajendran et al. Inhibition of endothelial PHD2 suppresses post-ischemic kidney inflammation through hypoxia-inducible factor-1
Jannaway et al. Thrombin-cleaved syndecan-3/-4 ectodomain fragments mediate endothelial barrier dysfunction
Wei et al. Inducible Fgf13 ablation enhances caveolae-mediated cardioprotection during cardiac pressure overload